0KW4.L
ResMed Inc
Q3 2025 Report
ResMed Inc (0KW4.L) Q3 2025 Financial Results: Strong Growth and Future Prospects...
Read full report
Executive Summary
In Q2 2025, ResMed Inc delivered impressive financial results showcasing strong revenue growth and significant improvements in profitability. The company's revenue reached $1.28 billion, reflecting a year-over-year increase of 10.26% and a sequential growth of 4.7%. The remarkable increase in net income to $344.6 million, up 65.05% year-over-year, underlines the effectiveness of ResMed's strategic initiatives focused on innovation and market expansion, particularly in its Sleep and Respiratory Care segments. Operating income rose by 51.67% compared to the prior year, indicating strong operational efficiency and a continuous push towards enhancing shareholder value.
Management attributed this performance to robust demand for respiratory devices amidst ongoing healthcare trends and increased focus on software applications for remote patient monitoring. This growth trajectory, along with effective cost management, positions ResMed favorably to capitalize on emerging opportunities within the healthcare sector while also navigating potential market challenges.
Key Performance Indicators
Revenue
1.28B
QoQ: 4.70% | YoY:10.26%
Gross Profit
751.28M
58.60% margin
QoQ: 4.75% | YoY:16.13%
Operating Income
417.24M
QoQ: 7.73% | YoY:51.67%
Net Income
344.62M
QoQ: 10.68% | YoY:65.05%
EPS
2.43
QoQ: 14.62% | YoY:71.13%
Revenue Trend
Margin Analysis
Key Insights
- **Revenue:** $1.28 billion (YoY: +10.26%, QoQ: +4.70%)
- **Gross Profit:** $751.3 million (YoY: +16.13%, QoQ: +4.75%)
- **Operating Income:** $417.2 million (YoY: +51.67%, QoQ: +7.73%)
- **Net Income:** $344.6 million (YoY: +65.05%, QoQ: +10.68%)
- **Earnings Per Share (EPS):** $2.43 (YoY: +71.13%, QoQ: +14.62%)